Influenza A Virus

• Relieves after effects of flu or flu-like symptoms * See symptoms on front panel.

Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.

1. 1Fatigue46211%
2. 2Diarrhoea3618.5%
3. 3Nausea3317.7%
4. 4Headache3057.1%
5. 5Dizziness2786.5%
6. 6Pain2746.4%
7. 7Drug Ineffective2596.1%
8. 8Arthralgia2475.8%
9. 9Off Label Use2465.8%
10. 10Dyspnoea2245.2%
11. 11Asthenia1944.5%
12. 12Malaise1914.5%
13. 13Pain In Extremity1834.3%
14. 14Injection Site Pain1784.2%
15. 15Vomiting1724.0%

Recent PubMed references pinned to Influenza A Virus as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Environmental samples, a sensitive and practical alternative to individual bird sampling in the surveillance of H9N2 vaccinated turkey flocks.
  The Journal of general virology · 2026 · Kalvelage L, Casteel M, Hartmann M, et al.
  PMID 42262844DOI 10.1099/jgv.0.002279
• Development of a pandemic H5N1 influenza vaccine using MDCK suspension cells: A scalable and efficient production platform.
  Human vaccines & immunotherapeutics · 2026 · Zhang S, Wang M, Jin D, et al.
  PMID 42258627DOI 10.1080/21645515.2026.2679784
• Development of Fit-for-Purpose, High Quality Proficiency Samples for Interlaboratory Evaluation of RT-PCR Detection of HPAI H5N1 in Milk.
  Food and environmental virology · 2026 · Smith EL, Jin Y, Miller MR, et al.
  PMID 42258002DOI 10.1007/s12560-026-09699-x
• Genetic Characterization of Swine Influenza Viruses in Thailand in 2019-2025 Reveals Novel Reassortants.
  Transboundary and emerging diseases · 2026 · Chaiyawong S, Phyu HW, Nasamran C, et al.
  PMID 42253333DOI 10.1155/tbed/9516354
• TurboID-Based Proximity Labeling Map Reveals the Protein Interaction Network and Anti-Viral Mechanism Against Influenza A H1N1.
  FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Wang M, Wang Z, Liu C, et al.
  PMID 42247242DOI 10.1096/fj.202600391R
• Deep learning-assisted, pathogenesis-informed lung histopathology scoring in preclinical mouse models of SARS-CoV-2 and influenza A infection.
  Frontiers in immunology · 2026 · An HW, Kim HA, Ha TH, et al.
  PMID 42245632DOI 10.3389/fimmu.2026.1826608
• In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
  Archives of virology · 2026 · Perdana WY, Tsuneki-Tokunaga A, Rahmi KA, et al.
  PMID 42243334DOI 10.1007/s00705-026-06665-7
• A new clade of H9N2 avian influenza virus circulating in Laos.
  Emerging microbes & infections · 2026 · Li J, Zhang C, Li R, et al.
  PMID 42243068DOI 10.1080/22221751.2026.2678641

The 10 most recently updated of 734 ClinicalTrials.gov registrations naming Influenza A Virus as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
  Completed · Phase 1 · Interventional · 80 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT07019883updated 2026-06-12
• Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections
  Not yet recruiting · Observational · 150 enrolled · Fabiana Sherine Ganem dos Santos
  NCT07643688updated 2026-06-11
• A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
  Recruiting · Phase 2 · Interventional · 96 enrolled · SynAct Pharma Aps
  NCT07633288updated 2026-06-11
• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
  Recruiting · Phase 1 · Phase 2 · Interventional · 50 enrolled · PEACHES BIOTECH
  NCT06684379updated 2026-06-10
• Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
  Recruiting · Phase 1 · Interventional · 56 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT07111078updated 2026-06-04
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
  Completed · Phase 2 · Interventional · 776 enrolled · GlaxoSmithKline
  NCT07121192updated 2026-05-28
• Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department
  Recruiting · Observational · 1,140 enrolled · Hospices Civils de Lyon
  NCT07601412updated 2026-05-22
• Vaccination Response Modulation With a Targeted Rapamycin Protocol Study
  Not yet recruiting · Phase 2 · Interventional · 60 enrolled · Central Adelaide Local Health Network Incorporated
  NCT07587801updated 2026-05-14
• Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
  Completed · Phase 1 · Phase 2 · Interventional · 980 enrolled · Sanofi
  NCT06695130updated 2026-05-05
• Woodsmoke Exposure, Influenza Infection, and Nasal Immunity
  Recruiting · Phase 4 · Interventional · 112 enrolled · University of North Carolina, Chapel Hill
  NCT06841913updated 2026-04-30

Frequently asked questions

What is Influenza A Virus used for?

According to FDA labeling, Influenza A Virus carries indications including: Relieves after effects of flu or flu-like symptoms * See symptoms on front panel.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.